Editorial
Copyright ©The Author(s) 2017.
World J Radiol. Feb 28, 2017; 9(2): 27-33
Published online Feb 28, 2017. doi: 10.4329/wjr.v9.i2.27
Table 1 Key features of positron emission tomography Response Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer 1999, Response Evaluation Criteria in Solid Tumors 1.1 and immune related Response Criteria
CategoryPERCISTEORTC 1999RECIST 1.1irRC
Target lesionsThe hottest single tumor lesion (SUL peak) at baseline 18F-FDG PETThe most 18F-FDG-avid lesions (SUV BSA). Number of lesions not specifiedMaximum, 5Maximum, 15 lesions
New lesionResults in progressive disease at first appearanceResults in progressive disease at first appearanceResults in progressive disease at first appearanceUp to 10 new visceral and 5 cutaneous lesions may be added to the sum of the products of the two largest perpendicular diameters of all index lesions at any time point
Complete responseCMR: Complete resolution of 18F-FDG uptake within the target lesion (< mean liver activity and indistinguishable from background/blood pool and no new 18F-FDG-avid lesions)CMR: Complete absence of 18F-FDG uptakeDisappearance of all target and nontarget lesions Nodes must regress to < 10 mm short axis No new lesions Confirmation required
Partial responsePMR: A reduction of a minimum of 30% in the target tumor 18F- FDG SUL peakPMR: A decrease in SUV > 25%≥ 30% decrease in tumor burden compared to baseline Confirmation required≥ 50% decrease in tumor burden compared with baseline1 Confirmation required
Progressive diseasePMD: A 30% increase in 18F-FDG SUL peak or advent of new 18F-FDG-avid lesionsPMD: An increase in SUV > 25% or appearance of new lesions≥ 20% + 5 mm absolute increase in tumor burden compared with nadir Appearance of new lesions or progression of nontarget lesions≥ 25% increase in tumor burden compared with baseline, nadir or reset baseline1 New lesions added to tumor burden Confirmation required
Stable diseaseSMD: Disease other than CMR, PMR or PMDSMD: Increase in SUV by < 25% or decrease in SUV by < 15%Neither partial response nor progressive disease